The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies

Autor: K. de Joode, W. S. van de Geer, G. J. L. H. van Leenders, P. Hamberg, H. M. Westgeest, A. Beeker, S. F. Oosting, J. M. van Rooijen, L. V. Beerepoot, M. Labots, R. H. J. Mathijssen, M. P. Lolkema, E. Cuppen, S. Sleijfer, H. J. G. van de Werken, A. A. M. van der Veldt

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)

Abstract Differences in the clinical course and treatment responses in individual patients with advanced renal cell carcinoma (RCC) can largely be explained by the different genomics of this disease. To improve the personalized treatment strategy and

Externí odkaz: https://doaj.org/article/0bbbda1544a74e2ab59f748e487111a1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature

Autor: J. M. van Berge Henegouwen, H. van der Wijngaart, L. J. Zeverijn, L. R. Hoes, M. Meertens, A. D. R. Huitema, L. A. Devriese, M. Labots, H. M. W. Verheul, E. E. Voest, H. Gelderblom

Publikováno v: Cancer Chemotherapy and Pharmacology, 90(1), 97-104. Springer Verlag
Cancer Chemotherapy and Pharmacology, 90(1), 97-104. SPRINGER
van Berge Henegouwen, J M, van der Wijngaart, H, Zeverijn, L J, Hoes, L R, Meertens, M, Huitema, A D R, Devriese, L A, Labots, M, Verheul, H M W, Voest, E E & Gelderblom, H 2022, ' Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer : a case series and review of literature ', Cancer Chemotherapy and Pharmacology, vol. 90, no. 1, pp. 97-104 . https://doi.org/10.1007/s00280-022-04437-z

Introduction The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated melanoma. BRAF muta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cb239b7fd18bf5826e94d10bb3a976a
https://research.vumc.nl/en/publications/bc9073e0-357d-4439-b7d7-5165678c433e

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.